TOKYO —

Millions worldwide carry the APOE4 gene variant, a significant genetic determinant for Alzheimer’s disease. Emerging research from the Gladstone Institutes is shedding new light on how this genetic predisposition may initiate detrimental changes in brain activity long before the onset of noticeable memory impairments. The groundbreaking study, published in the esteemed journal Nature Aging, has meticulously mapped a molecular cascade triggered by APOE4, offering a potential avenue for therapeutic intervention to reverse some of these early-stage alterations.

At the core of these findings is the identification of the protein Nell2 as a key player in the APOE4-driven pathological process. Researchers observed that APOE4 significantly amplifies the production of Nell2 within neurons. This surge in Nell2 levels was directly linked to neurons becoming smaller and exhibiting unusually high levels of electrical activity, a phenomenon known as hyperactivity. Crucially, the study demonstrated a predictive relationship: mice exhibiting greater brain hyperactivity during their youth subsequently developed more pronounced memory deficits in later life. This discovery marks a significant advancement, providing the first direct examination of APOE4’s impact on neuronal function across different ages and establishing a clear link between early cellular changes and later cognitive decline.

The Pervasive Influence of APOE4

The apolipoprotein E (APOE) gene exists in three common forms: APOE2, APOE3, and APOE4. While all play a role in lipid transport and cellular repair, APOE4 stands out due to its potent association with increased Alzheimer’s disease risk. Approximately one in four individuals in the general population carries at least one copy of the APOE4 variant. This prevalence escalates dramatically among those diagnosed with Alzheimer’s, with estimates suggesting that 60% to 75% of individuals with the disease possess the APOE4 allele. This disproportionate representation underscores APOE4’s status as the strongest known genetic risk factor for the neurodegenerative disorder, a condition that affects millions globally, with an aging population worldwide leading to a projected increase in cases in the coming decades.

A Molecular Cascade: From Gene to Hyperactivity

The research team at Gladstone Institutes embarked on a detailed investigation using sophisticated mouse models designed to mimic human APOE genotypes. Their meticulous examination of brain activity in young mice revealed a striking difference: those carrying the APOE4 variant exhibited excessive neuronal firing in specific regions of the hippocampus. The hippocampus, a brain structure critically involved in learning and memory formation, is one of the first areas to be affected by Alzheimer’s disease. The observed hyperactivity in these critical memory circuits in young APOE4 mice mirrored findings in human APOE4 carriers, where elevated brain activity has been noted even before middle age and has been correlated with later cognitive decline.

The study further delved into the structural correlates of this hyperactivity. Neurons within the affected hippocampal regions of APOE4 mice were found to be smaller compared to their counterparts in mice carrying the APOE3 variant, a form of the gene associated with a lower risk of Alzheimer’s. This reduction in neuronal size can make them more sensitive to external stimuli, thereby increasing their propensity for excessive firing. In contrast, neurons in APOE3 mice did eventually show increased excitability, but this shift typically occurred much later in life, suggesting that APOE4 accelerates a process that resembles normal aging, but at a significantly faster pace.

Neuronal Autonomy: APOE4’s Intracellular Origin

A prevailing hypothesis in the field had long suggested that APOE4’s detrimental effects were primarily mediated by astrocytes, glial cells that provide crucial support to neurons. This was based on the observation that astrocytes are the primary producers of APOE in a healthy brain. However, the new research challenges this long-held assumption. The Gladstone team’s experiments demonstrated that the hippocampal hyperactivity observed in APOE4 mice was independently driven by APOE4 produced within the neurons themselves. When researchers genetically engineered the mice to lack APOE4 specifically in astrocytes, no significant change in neuronal activity was observed. Conversely, when APOE4 was removed from neurons, these cells returned to a more normal size and functional state. This finding is pivotal, indicating that the primary site of APOE4’s pathological action, at least in the context of early hippocampal hyperactivity, lies within the neurons themselves.

Nell2: A Promising Target for Intervention

With the understanding that APOE4 within neurons was driving the observed hyperactivity, the researchers sought to identify the specific molecular mechanisms involved. Their analysis of gene expression patterns within hippocampal neurons from APOE4 mice pinpointed Nell2 as a key protein present at unusually high levels. Nell2 had not been previously implicated in the context of APOE4 and Alzheimer’s, but independent research had noted elevated Nell2 levels in the brains of Alzheimer’s patients, with higher concentrations correlating with more severe cognitive impairment.

To test the hypothesis that elevated Nell2 was responsible for the APOE4-induced neuronal dysfunction, the scientists employed CRISPRi (CRISPR interference), a gene-editing technique that can reduce gene expression without permanently altering the DNA sequence. By selectively lowering Nell2 production in hippocampal neurons of adult APOE4 mice, they observed a remarkable reversal of the pathological changes. The neurons grew larger and their electrical activity normalized. This direct correlation strongly suggests that elevated Nell2 is the proximate cause of the excessive neuronal activity observed in APOE4-carrying brains.

Reversing the Tide: Hope for Early Intervention

The ability to reverse these detrimental changes in adult mice by reducing Nell2 levels offers a beacon of hope for potential therapeutic strategies. "What’s exciting about Nell2 is that we were able to reverse the disease manifestations in adult mice by lowering its level," stated Dr. Yadong Huang, associate director of the Gladstone Institute of Neurological Disease and a senior author of the study. "That tells us the damage is not irreversible, and that there may be a window for intervention even after disease processes have been triggered."

This discovery opens up the possibility of developing novel drugs that target Nell2. Such therapies could potentially mitigate the risk of cognitive decline in individuals carrying the APOE4 gene variant by normalizing neuronal activity in critical brain circuits before irreversible damage occurs. This approach represents a significant shift towards proactive, preventative strategies in Alzheimer’s research, moving beyond symptom management to addressing the root causes of the disease at a molecular level.

Broader Implications and Future Directions

The findings from the Gladstone Institutes have profound implications for the field of Alzheimer’s research and for millions of individuals at risk. By elucidating the molecular pathway linking APOE4 to early neuronal dysfunction, the study provides a tangible target for therapeutic development. The predictive power of early brain hyperactivity, as demonstrated in the mouse models, suggests that future diagnostic tools could potentially identify individuals at high risk based on their brain activity patterns long before clinical symptoms emerge.

Dr. Misha Zilberter, principal staff research scientist at Gladstone and a senior author of the study, emphasized the significance of their findings: "To the best of our knowledge, this is the first study that has directly examined what APOE4 does to the function of neurons at different ages. We found fundamental changes in brain circuits occurring in young mice that still had normal learning and memory, and importantly, that those changes predicted the development of cognitive deficits at older ages."

The research was generously supported by funding from multiple branches of the National Institutes of Health, including the National Institute on Aging (NIA), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Center for Research Resources (NCRR). This robust financial backing underscores the recognized importance of this line of inquiry in the ongoing global effort to combat Alzheimer’s disease.

Moving forward, researchers will likely focus on translating these findings into human studies. This will involve developing methods to accurately measure Nell2 levels in human subjects and evaluating the safety and efficacy of Nell2-targeting interventions. The prospect of developing a therapy that can intercept the APOE4-driven cascade early in its progression offers a renewed sense of optimism in the long and arduous fight against Alzheimer’s disease, a condition that continues to place an immense burden on individuals, families, and healthcare systems worldwide. The identification of Nell2 as a critical mediator not only deepens our understanding of APOE4’s complex role but also provides a concrete and promising avenue for developing effective treatments and preventive strategies.